Northwestern Mutual Wealth Management Co. Has $58.56 Million Position in IQVIA Holdings Inc. $IQV

Northwestern Mutual Wealth Management Co. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 3.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 259,800 shares of the medical research company’s stock after purchasing an additional 8,072 shares during the period. Northwestern Mutual Wealth Management Co. owned about 0.15% of IQVIA worth $58,561,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in IQV. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $25,000. Physician Wealth Advisors Inc. raised its holdings in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the last quarter. International Assets Investment Management LLC bought a new position in IQVIA in the 4th quarter valued at approximately $27,000. Westside Investment Management Inc. raised its holdings in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in IQVIA in the 3rd quarter valued at approximately $30,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 0.5%

IQVIA stock opened at $182.03 on Friday. The firm has a 50 day moving average price of $170.34 and a two-hundred day moving average price of $196.18. The firm has a market cap of $30.38 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 1.74 and a beta of 1.18. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 52-week low of $136.41 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has initiated a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Evercore reiterated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. Royal Bank Of Canada assumed coverage on shares of IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Finally, Stifel Nicolaus dropped their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.